1. Articles in category: Genomics

    1-24 of 205 1 2 3 4 5 6 7 8 9 »
    1. Shallow whole genome sequencing on circulating cell-free DNA allows reliable non-invasive copy number profiling in neuroblastoma patients.

      Shallow whole genome sequencing on circulating cell-free DNA allows reliable non-invasive copy number profiling in neuroblastoma patients.

      Clin Cancer Res. 2017 Jul 14;:

      Authors: Van Roy N, Van der Linden M, Menten B, Dheedene A, Vandeputte C, Van Dorpe J, Laureys G, Renard M, Sante T, Lammens T, De Wilde B, Speleman F, De Preter K

      Read Full Article
      Mentions: MYCN ATRX
    2. Pediatric MATCH: Pan-FGFR Tyrosine Kinase Inhibitor JNJ-42756493 in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With FGFR 1/2/3/4 Mutations

      Conditions :   Advanced Malignant Solid Neoplasm;   FGFR1 Gene Mutation;   FGFR2 Gene Mutation;   FGFR3 Gene Mutation;   FGFR4 Gene Mutation;   Histiocytosis;   Recurrent Central Nervous System Neoplasm;   Recurrent Childhood Non-Hodgkin Lymphoma;   Recurrent Malignant Solid Neoplasm;   Recurrent Neuroblastoma;   Refractory Central Nervous System Neoplasm;   Refractory Malignant Solid Neoplasm;   Refractory Neuroblastoma;   Refractory Non-Hodgkin Lymphoma;   Stage III Childhood Non-Hodgkin Lymphoma;   Stage IV Childhood Non-Hodgkin Lymphoma Interventions :   Other: Laboratory Biomarker Analysis;   Drug: pan-FGFR Tyrosine Kinase Inhibitor JNJ-42756493;   Other: Pharmacological Study Sponsor :   National Cancer Institute (NCI) Not yet recruiting - verified June 2017

      Read Full Article
      Mentions: Refractory
    3. Neuroblastoma in children: Update on clinicopathologic and genetic prognostic factors.

      Neuroblastoma in children: Update on clinicopathologic and genetic prognostic factors.

      Pediatr Hematol Oncol. 2017 Jun 29;:1-21

      Authors: Ahmed AA, Zhang L, Reddivalla N, Hetherington M

      Abstract Neuroblastoma is the most common extracranial solid tumor in childhood accounting for 8-10% of all childhood malignancies. The tumor is characterized by a spectrum of histopathologic features and a heterogeneous clinical phenotype.

      Read Full Article
      Mentions: MYCN
    4. New research points to potential targeted treatments of neuroblastoma tumours

      New research points to potential targeted treatments of neuroblastoma tumours

      Genetic variations appear to pre-dispose children to developing certain severe forms of neuroblastoma, according to new research by the University of Chicago Medicine.

      The findings lay the groundwork for developing more targeted treatments for...

      Read Full Article
      Mentions: MYCN
    5. Potential for more targeted treatments of neuroblastoma tumors

      Genetic variations appear to pre-dispose children to developing certain severe forms of neuroblastoma, according to new research. The findings lay the groundwork for developing more targeted treatments for particularly deadly variations of the cancer.

      Read Full Article
      Mentions: MYCN
    6. New research points to potential for more targeted treatments of neuroblastoma tumors

      New research points to potential for more targeted treatments of neuroblastoma tumors

      ( University of Chicago Medical Center ) Genetic variations appear to pre-dispose children to developing certain severe forms of neuroblastoma, according to new research by the University of Chicago Medicine. The findings lay the groundwork for developing more targeted treatments for particularly deadly variations of the cancer.

      Read Full Article
      Mentions: MYCN
    7. Precision Medicine in Pediatric Oncology: Translating Genomic Discoveries into Optimized Therapies.

      "Survival of children with cancers has dramatically improved over the past several decades.  This success has been achieved through improvement of combined modalities in treatment approaches, intensification of cytotoxic chemotherapy for those with high-risk disease and refinement of risk stratification incorporating novel biologic markers in addition to traditional clinical and histologic features. Advances in cancer genomics have shed important mechanistic insights on disease biology and have identified "driver" genomic alterations, aberrant activation of signaling pathways, and epigenetic modifiers that can be targeted by novel agents.  Thus, the recently described genomic and epigenetic landscapes of many childhood cancers have expanded the ...

      Read Full Article
    8. Genomic analysis-integrated whole-exome sequencing of neuroblastomas identifies genetic mutations in axon guidance pathway.

      Genomic analysis-integrated whole-exome sequencing of neuroblastomas identifies genetic mutations in axon guidance pathway.

      Oncotarget. 2017 May 23;:

      Authors: Li Y, Ohira M, Zhou Y, Xiong T, Luo W, Yang C, Li X, Gao Z, Zhou R, Nakamura Y, Kamijo T, Kaneko Y, Taketani T, Ueyama J, Tajiri T, Zhang H, Wang J, Yang H, Yin Y, Nakagawara A

      Read Full Article
      Mentions: ALK
    9. Results Indicate That Larotrectinib Is Effective as the First Novel Targeted Therapy to Show a Consistent Response across Multiple Tumor Types in Adult and Pediatric Patients

      Results Indicate That Larotrectinib Is Effective as the First Novel Targeted Therapy to Show a Consistent Response across Multiple Tumor Types in Adult and Pediatric Patients

      Larotrectinib (LOXO-101) has demonstrated consistent and durable antitumor activity in tropomyosin receptor kinase (TRK) fusion cancers across a wide range of patient ages and tumor types and was well tolerated by patients, according to results from three clinical trials presented today at the annual meeting of the American Society of Clinical Oncology in Chicago.

      Read Full Article
    10. AACR Publishes First Set of Screening Recommendations Emerging from Childhood Cancer Predisposition Workshop

      AACR Publishes First Set of Screening Recommendations Emerging from Childhood Cancer Predisposition Workshop

      ​PHILADELPHIA — The American Association for Cancer Research (AACR) has published its first set of consensus screening recommendations for children with common cancer predisposition syndromes in Clinical Cancer Research, a journal of the AACR. These recommendations emerged from the Childhood Cancer Predisposition Workshop held by the AACR Pediatric Cancer Working Group in October 2016.

      Read Full Article
      Mentions: Imaging
    11. Study finds more childhood cancer survivors would likely benefit from genetic screening

      Study finds more childhood cancer survivors would likely benefit from genetic screening

      WASHINGTON, April 3, 2017 /PRNewswire/ -- Twelve percent of childhood cancer survivors carry germline mutations that put them or their children at increased risk of developing cancer, according to a landmark study presented today at the annual meeting of the American Association for...

      Read Full Article
    12. Next-generation sequencing reveals germline mutations in an infant with synchronous occurrence of nephro- and neuroblastoma.

      Next-generation sequencing reveals germline mutations in an infant with synchronous occurrence of nephro- and neuroblastoma.

      Pediatr Hematol Oncol. 2016 May;33(4):264-75

      Authors: Theruvath J, Russo A, Kron B, Paret C, Wingerter A, El Malki K, Neu MA, Alt F, Staatz G, Stein R, Seidmann L, Prawitt D, Faber J

      Read Full Article
      Mentions: ALK
    13. Transcriptomic profiling of 39 commonly-used neuroblastoma cell lines.

      Transcriptomic profiling of 39 commonly-used neuroblastoma cell lines.

      Sci Data. 2017 Mar 28;4:170033

      Authors: Harenza JL, Diamond MA, Adams RN, Song MM, Davidson HL, Hart LS, Dent MH, Fortina P, Reynolds CP, Maris JM

      Abstract Neuroblastoma cell lines are an important and cost-effective model used to study oncogenic drivers of the disease.

      Read Full Article
      Mentions: ALK MYCN
    14. Neuroblastoma treatment in the post-genomic era.

      Neuroblastoma treatment in the post-genomic era.

      J Biomed Sci. 2017 Feb 08;24(1):14

      Authors: Esposito MR, Aveic S, Seydel A, Tonini GP

      Abstract Neuroblastoma is an embryonic malignancy of early childhood originating from neural crest cells and showing heterogeneous biological, morphological, genetic and clinical characteristics.

      Read Full Article
      Mentions: Treatment ALK MYCN
    15. New assay shows promise to advance personalized therapy for cancer patients

      New assay shows promise to advance personalized therapy for cancer patients

      ( Elsevier Health Sciences ) The National Cancer Institute's NCI-MATCH (Molecular Analysis for Therapy Choice) is a large, ongoing clinical trial that matches tumors to therapies based on the tumor's genetic characteristics. A report in The Journal of Molecular Diagnostics confirms that the assay tailored for this trial is highly sensitive for detecting genetic mutations from a variety of tumor tissue and, for the first time, has been reproduced with accuracy by multiple clinical laboratories, laying the groundwork for future clinical utility.

      Read Full Article
      Mentions: Diagnostics
    16. Neuroblastoma survivors are at increased risk for second malignancies: A report from the International Neuroblastoma Risk Group Project.

      Neuroblastoma survivors are at increased risk for second malignancies: A report from the International Neuroblastoma Risk Group Project.

      Eur J Cancer. 2016 Dec 26;72:177-185

      Authors: Applebaum MA, Vaksman Z, Lee SM, Hungate EA, Henderson TO, London WB, Pinto N, Volchenboum SL, Park JR, Naranjo A, Hero B, Pearson AD, Stranger BE, Cohn SL, Diskin SJ

      Read Full Article
      Mentions: INRG
    17. Enrichment of Targetable Mutations in the Relapsed Neuroblastoma Genome.

      "However, recent studies have shown that the mutational burden increases at relapse, likely as a result of clonal evolution of mutation-carrying cells during primary treatment. To inform the development of personalized therapies, we sought to further define the frequency of potentially actionable mutations in neuroblastoma, both at diagnosis and after chemotherapy. We performed a retrospective study to determine mutation frequency, the only inclusion criterion being availability of cancer gene panel sequencing data from Foundation Medicine. We analyzed 151 neuroblastoma tumor samples: 44 obtained at diagnosis, 42 at second look surgery or biopsy for stable disease after chemotherapy, and 59 at ...

      Read Full Article
      Mentions: ALK
    1-24 of 205 1 2 3 4 5 6 7 8 9 »
  1. Categories

    1. Research:

      Cancer Cell, Case Report, Cells and Stem Cells, Clinical Research, Conferences, Disease Classification, Drug, Drug Delivery, Drug Resistance, Epigenetics and Epigenomics, General, Genetics, Genomics, Guidelines, Immune Therapy, Induction, Long Term Effects, Low / Intermediate Risk, Nanotechnology, Olfactory Neuroblastoma, Onco-Fertility, Oncogenesis, Other Cancers, Personalized Medicine, Pharma, Pre-Clinical, Prognostics, PubMed, Review, Small Molecules, Surgery, Survivorship, Trials, Tumor Biology, Virotherapy
    2. Business:

      Funding, IP, Pharma
    3. Non-Profit:

      Advocacy, Charity, Events, Foundation, Funding, Human Interest
    4. Press Release:

      Announcement, News, Pharma
    5. General:

      Adolescent and Young Adults, Bioethics, Blog, Burden of Treatment, Children & Families, Diagnosis and Detection, Drug Development, Epidemiology, Imaging, Incidence, Information, News, Overview of the Disease, Pain Control, Palliative Care, Psychosocial, Regulation, Side-Effects, Social, Supportive Care, Treatment
    6. Media:

      Audio, Blogs, Video
  2. Popular Articles

  3. Researches in the News

    1. (2 articles) MYCN
    2. (1 articles) ATRX
  4. Treatments in the News

    1. (1 articles) Refractory